Catalog No.S1801 Synonyms: AH19065
Molecular Weight(MW): 350.86
Ranitidine is a histamine H2-receptor antagonist, used to treat stomach or intestinal ulcers.
Purity & Quality Control
Choose Selective Histamine Receptor Inhibitors
|Description||Ranitidine is a histamine H2-receptor antagonist, used to treat stomach or intestinal ulcers.|
Ranitidine sensitizes hepatocytes to killing by cytotoxic products from activated neutrophils, whereas Famotidine lacks this ability.  Ranitidine inhibits the production of tumor necrosis factor-alpha (TNF-alpha) in monocytes stimulated with lipopolysaccharide in vitro.  Ranitidine reduces the Kel of morphine dose-dependently with a maximum effect of 50%, and increases the relative concentration of morphine-6-glucuronide to morphine-3-glucuronide in isolated guinea pig hepatocytes. Ranitidine gradually decreases the morphine-3-glucuronide/morphine-6-glucuronide ratio by up to 21%. 
|In vivo||Ranitidine results in liver injury as evidence by increased in serum alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase activities within 6 hours after Ranitidine administration in rats.  Ranitidine inhibits hepatic ischemia/reperfusion-induced increase in hepatic tissue levels of TNF-alpha, cytokine-induced neutrophil chemoattractant, and hepatic accumulation of neutrophils in rats.  Ranitidine cotreatment enhances LPS-induced coagulation prior to liver injury, and anticoagulants reduce liver damage in LPS/RAN-treated rats. Ranitidine /LPS-treated rats results in the formation of fibrin clots in liver sinusoids, and prevention of fibrin deposition associated with reduced hepatocellular injury. Ranitidine cotreatment enhances the LPS-induced TNF increase before the onset of hepatocellular injury in rats.  Ranitidine displays anxiolytic effects in the elevated plus-maze as indicated by an increase in time spent in the open arms, more open-arm scanning and more end-excursions in rats. |
-  Luyendyk JP, et al. J Pharmacol Exp Ther,?003, 307(1), 9-16.
-  Okajima K, et al. J Pharmacol Exp Ther,?002, 301(3), 1157-1165.
-  Aasmundstad TA, et al. Pharmacol Toxicol, 1998, 82(6), 272-279.
|In vitro||DMSO||70 mg/mL (199.5 mM)|
|Water||70 mg/mL (199.5 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02960555||Recruiting||Myeloma||M.D. Anderson Cancer Center|Sanofi||February 8, 2017||Phase 2|
|NCT03011463||Suspended||Pharmacokinetics|Inhibition Enzyme|Drug Interaction Potentiation||University Medicine Greifswald||November 2016||Phase 1|
|NCT02953210||Enrolling by invitation||Pain, Postoperative|Anesthesia Complication|Nausea|Vomiting|Ileus Paralytic|Hemodynamic Instability||Federal University of São Paulo|Faculdade de Ciências Médicas da Santa Casa de São Paulo||November 2016||Phase 4|
|NCT02700087||Recruiting||Laryngomalacia|Acid Reflux|Stridor||Stanford University||February 2016||--|
|NCT02441673||Not yet recruiting||Post Anaesthetic Shivering||Lagos State Health Service Commission||September 2015||Phase 2|
|NCT02441894||Completed||Prostate Cancer||Sanofi||April 2015||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.